Top of this page
Skip navigation, go straight to the content

Investors UCB equity story

Since 2015, UCB has embarked on a very important change journey:

the Patient Value Strategy

In 2019, we entered the next phase of our Patient Value Strategy:

“Accelerate & Expand” (2019-2021)

 

 
During this phase, we are accelerating our growth potential by further improving our ability to demonstrate differentiation of our medicines, by accelerating our development timelines through new approaches and by improving patients’ access to our key medicines.

The evolving COVID-19 pandemic is profoundly impacting our lives, and places tremendous strain on healthcare systems and society at large. Since the start of the crisis, UCB has taken measures to protect our colleagues around the world, to stand by patients, to help our communities and take our part in the global response to the pandemic. We know that it is our responsibility to help where we can make an impact. Find out what actions UCB has taken here.

"Accelerate & Expand" (2019-2021)

Making significant progress towards this ambitious goal...

Focus on patients

5 core products

     

Briviact  

2 recent launches

Evenity      Nayzilam

Strengthen R&D

5 Phase late stage assets

bimekizumab

zilucoplan

rozanolixizumab

dapirolizumab pegol

Staccato® alprazolam

 

identify & act on opprotunities

3 major acquisitions & many partnerships

Ra Pharma   Engage

Ferring     Handl THerapeutics

     

 
 
 

2020 achievements

  • Cimzia® available to Japanese patients living with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma
  • Broadening the patient population for Vimpat® with approvals in the U.S., Europe and Japan as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS)
  • Promising progress for bimekizumab: 

Phase 3b study BE RADIANT, comparing bimekizumab to secukinumab for the treatment of adults with moderate-to-severe plaque psoriasis met its primary end points.

Filing in the U.S. & EU for the treatment of adults with moderate-to-severe plaque psoriasis

  • Acquisition of Ra Pharma, Engage Therapeutics & Handl Therapeutics
  • Partnerships signed with Ferring Pharmaceuticals, Roche / Genentech, Lacerta Therapeutics, Microsoft

2021 achievements

  • Launch of Nile AI, Inc., a new independent company created to improve care for people living with epilepsy, their caregivers, and healthcare providers (HCPs). 
  • Cimzia®: UCB received the Declaration of Conformity (CE) Mark for ava Connect®, a device designed to help improve the patient experience and medication adherence for Cimzia® by providing a comfortable injection and recording the patient’s injection administration.
  • Further progress for bimekizumab:

In June 2021, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending granting a marketing authorization for bimekizumab, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

The U.S. Food and Drug Administration (FDA) has set the Prescription Drug User Fee Act (PDUFA) date for UCB’s Biologics License Application for bimekizumab to October 15, 2021.

Our key medicines

We bring solutions to people living with neurological or immunological diseases.

Cimzia

Peak sales guidance

 

  • Cimzia® > € 2 billion by 2024  
  • Vimpat® > € 1.5 billion by 2022  
  • Briviact® > € 600 million by 2026
 
Keppra® reached peak sales of € 1.2 billion in 2008.

Vimpat

 

Keppra logo

Neupro

 
 

Our pipeline

In a challenging environment, our pipeline builds the basis of UCB’s sustainable long-term growth.

We continued to create value for patients, advancing our pipeline of potential solutions for severe diseases, expanding our capabilities by investing in state-of-the-art scientific platforms and medical advances, and further progress on our digital business transformation journey.

 

5 late stage assets 

  1. Bimekizumab in psoriasis (PsO), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and hidradenitis suppurativa (HS)
  2. Zilucoplan in Myasthenia Gravis (MG)
  3. Rozanolixizumab in Immune Thrombocytopenia (ITP), Myasthenia Gravis (MG), MOG-antibody disease, autoimmune encephalitis (AIE)
  4. Dapirolizumab pegol in systemic lupus erythematosus (SLE) in partnership with Biogen
  5. Staccato® alprazolam in acute epileptic seizure

Clinical studies index

UCB is committed to sharing information on studies and making study results publicly accessible. You will find below links to the clinical studies (Phase 2-4) of our main R&D projects.

More information about our clinical studies index and our position paper are available here.

MOLECULE
MODALITY
THERAPEUTIC AREA
INDICATION
PHASE
1 2 3 Filing
INFORMATION
Bimekizumab
  • Monoclonal antibody
    Immunology
    Psoriasis
    Filing
    Filing in the USA

    Bimekizumab is an investigational humanized monoclonal IgG antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes.

  • Monoclonal antibody
    Immunology
    Psoriatic arthritis
    Phase 2.5
    Topline results end 2021

    Bimekizumab is an investigational humanized monoclonal IgG antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes.

  • Monoclonal antibody
    Immunology
    Axial spondyloarthritis
    Phase 2.5
    Topline results end 2021

    Bimekizumab is an investigational humanized monoclonal IgG antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes.

  • Monoclonal antibody
    Immunology
    Hidradenitis suppurativa
    Phase 2.5
    Topline results H2 2022

    Bimekizumab is an investigational humanized monoclonal IgG antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes.

Zilucoplan
  • Macrocyclic peptide
    Neurology
    Myasthenia gravis
    Phase 2.5
    Topline results Q4 2021

    Zilucoplan is an investigational macrocyclic peptide inhibitor of complement component 5 (C5). The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to zilucoplan for the treatment of myasthenia gravis.

    Zilucoplan is being investigated for the treatment of amyotrophic lateral sclerosis (ALS) as part of the HEALEY ALS Platform Trial.

Rozanolixizumab
  • Monoclonal antibody
    Neurology
    Myasthenia gravis
    Phase 2.5
    Topline results Q1 2022

    Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.

  • Monoclonal antibody
    Immunology
    Immune thrombocytopenia
    Phase 2.5
    Topline results H2 2022

    Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.

  • Monoclonal antibody
    Neurology
    Myelin oligodendrocyte glycoprotein (MOG) antibody disease
    Phase 2
    Phase 3 to start Q4 2021

    Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.

  • Monoclonal antibody
    Neurology
    Autoimmune encephalitis
    Phase 1
    Phase 2 to start in Q3 2021 / topline results H1 2024

    Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.

Dapirolizumab pegol
  • Monoclonal antibody
    Immunology
    Systemic lupus erythematosus
    Phase 2.5
    Topline results H1 2024

    Dapirolizumab pegol is an investigational humanised monovalent pegylated Fab antibody fragment against the CD40 ligand (CD40L). Through interactions with its receptor, CD40, CD40L plays an important role in regulating interactions between T cells and other immune cells and thus affects several important functional events thought to be involved in autoimmune disease.

    Dapirolizumab pegol is being co-developed with Biogen.

Staccato® (alprazolam)
  • Small molecule
    Neurology
    Active epileptic seizure
    Phase 2
    Phase 3 to start Q4 2021

    Staccato® Alprazolam is an orally-inhaled investigational therapy designed to be used as a single-use epileptic seizure rescue therapy that combines the Staccato® delivery technology with alprazolam, a benzodiazepine.

Bepranemab
  • Monoclonal antibody
    Neurology
    Alzheimer's disease
    Phase 1.5
    Topline results H1 2025

    Bepranemab is an investigational recombinant, humanised, full length IgG4 monoclonal anti-tau antibody with specificity for human tau protein.

    Bepranemab is being co-developed with Roche/Genentech.

UCB0599
  • Small molecule
    Neurology
    Parkinson's disease
    Phase 1.5
    Topline results H2 2023

    UCB0599 is an investigational small molecule that prevents the pathological misfolding and accumulation of alpha-synuclein, a protein which plays a role in Parkinson’s disease (PD) pathology. Inhibition of alpha-synuclein misfolding has the potential to slow down the progression of PD.

    UCB0599 belongs to a series of molecules discovered by Neuropore, which were in-licensed by UCB in 2014.

 

Questions?

Contact the IR team and we will do our best to help you!